Percutaneous isolated hepatic perfusion for chemotherapy: A phase 1 study

Archives of Surgery

Volumn 138, Issue 3, 2003, Pages 325-332

  Savier, Eric ^a   Azoulay, Daniel ^a   Huguet, Emmanuel ^a   Lokiec, François ^b   Gil Delgado, Marian ^a   Bismuth, Henri ^a  

^a HÔPITAL PAUL BROUSSE   (France)

^b CENTRE RENÉ HUGUENIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; FLUOROURACILE; FOLINATE CALCIUM; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MELPHALAN; MITOMYCIN C; NAVELBINE; OXALIPLATIN; TRASTUZUMAB;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; ASCITES; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONCENTRATION RESPONSE; EXTRACORPOREAL CIRCULATION; FEMALE; HEPATIC ARTERY; HUMAN; LAPAROTOMY; LIVER ANGIOGRAPHY; LIVER BLOOD VESSEL; LIVER METASTASIS; LIVER PERFUSION; LIVER TOXICITY; LIVER TUMOR; MALE; MORBIDITY; MORTALITY; NEUTROPENIA; PLEURA EFFUSION; PRIORITY JOURNAL; SYSTEMIC CIRCULATION; TREATMENT OUTCOME; VEIN OCCLUSION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BREAST NEOPLASMS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CHOLANGIOCARCINOMA; COLORECTAL NEOPLASMS; FATAL OUTCOME; FEMALE; HUMANS; LAPAROTOMY; LIVER NEOPLASMS; MALE; MELPHALAN; MIDDLE AGED; RADIOGRAPHY, INTERVENTIONAL; STOMACH NEOPLASMS;

EID: 0037336019     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.138.3.325     Document Type: Article

References (46)

1. Ruers T, Bleichrodt RP. Treatment of liver metastases: an update on the possibilities and results. Eur J Cancer. 2002;38:1023-1033.
2. Bismuth H, Adam R, Lévi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996;224:509-520.
3. Azoulay D, Castaing D, Smail A, et al. Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. Ann Surg. 2000;231:480-486.
4. Ruers TJ, Joosten J, Jager GJ, Wobbes T. Long-term results of treating hepatic colorectal metastases with cryosurgery. Br J Surg. 2001;88:844-849.
5. Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H. Two-stage hepatectomy: a planned strategy to treat irresectable liver tumors. Ann Surg. 2000;232:777-785.
6. Frei E, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med. 1980;69:585-594.
7. Link KH, Leder G, Pillasch J, et al. In vitro concentration response studies and in vitro phase II tests as the experimental basis for regional chemotherapeutic protocols. Semin Surg Oncol. 1998;14:189-201.
8. Leonard RC. The advancement of high-dose chemotherapy and dose intensification schedules. Ann Oncol. 1997;8(suppl 3):S3-S6.
9. Leff RS, Thompson JM, Johnson DB, et al. Phase II trial of high-dose melphalan and autologous bone marrow transplantation for metastatic colon carcinoma. J Clin Oncol. 1989;4:1586-1591.
10. Ravikumar TS, Pizzorno G, Bodden W, et al. Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors. J Clin Oncol. 1994;12:2723-2736.
11. Curley SA, Newman RA, Dougherty TB, et al. Complete hepatic venous isolation and extracorporeal chemofiltration as treatment for human heptocellular carcinoma: a phase I study. Ann Surg Oncol. 1994;1:389-399.
12. Ku Y, Tominaga M, Iwasaki T, et al. Percutaneous hepatic venous isolation and extracorporeal charcoal hemoperfusion for high-dose intraarterial chemotherapy in patients with colorectal hepatic metastases. Surg Today. 1996;26:305-313.
13. Hwu WJ, Salem RR, Pollak J, et al. A clinical-pharmacological evaluation of percutaneous isolated hepatic infusion of doxorubicin in patients with unresectable liver tumors. Oncol Res. 1999;11:529-537.
14. Eggermont AMM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. Ann Surg. 1996;224:756-765.
15. Guadagni S, Fiorentini G, Palumbo G, et al. Hypoxic pelvic perfusion with mitomycin C using a simplified balloon-occlusion technique in the treatment of patients with unresectable locally recurrent rectal cancer. Arch Surg. 2001;136:105-112.
16. Pass Hi, Mew DJ, Kranda KC, Temeck BK, Donington JS, Rosenberg SA. Isolated lung perfusion with tumor necrosis factor for pulmonary metastases. Ann Thorac Surg. 1996;61:1609-1617.
17. Aust JB, Ausman RK. The technique of liver perfusion. Cancer Chemother Rep. 1960;10:23-33.
18. Skibba JL, Quebbeman EJ. Tumoricidal effects and patient survival after hyperthermic liver perfusion. Arch Surg. 1986;121:1266-1271.
19. Schwemmle K, Link KH, Rieck B. Rationale and indications for perfusion in liver tumors: current data. World J Surg. 1987;11:534-540.
20. Aigner KR. Isolated liver perfusion: 5 years experience. Reg Cancer Treat. 1988; 1:11-20.
21. Hafström L, Holmberg SB, Naredi PL, et al. Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy. Surg Oncol. 1994;3:103-108.
22. Marinelli A, Maurits de Brauw L, Beerman H, et al. Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver. Jpn J Clin Oncol. 1996;26:341-350.
23. Alexander HR, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol. 1998;16:1479-1489.
24. Oldhafer KJ, Lang H, Frerker M, et al. First experience and technical aspects of isolated liver perfusion for extensive liver metastasis. Surgery. 1998;123:622-631.
25. Marinelli A, Vahrmeijer AL, van de Velde CJH. Phase I/II studies of isolated hepatic perfusion with mitomycin C or melphalan in patients with colorectal cancer hepatic metastases. Recent Results Cancer Res. 1998;147:83-94.
26. de Vries MR, Rinkes IH, van de Velde CJH, et al. Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans. Recent Results Cancer Res. 1998;147:107-119.
27. Lindnér P, Fjälling M, Hafström L, et al. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor and melphalan. Eur J Surg Oncol. 1999;25:179-185.
28. Alexander HR, Libutti SK, Bartlett DL, Puhlmann M, Fraker DL, Bachenheimer LC. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2000;6:3062-3070.
29. Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery. 2001; 129:176-187.
30. Vahrmeijer AL, van Dierendonck JH, Keizer HJ, et al. Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver. Br J Cancer. 2000;82:1539-1546.
31. Azoulay D, Raccuia JS, Castaing D, Bismuth H. Right portal vein embolization in preparation for major hepatic resection. J Am Coll Surg. 1995;181:266-269.
32. Savier E, Lokiec F, Le Fur S. Chimiothérapie par perfusion isolée du foie avec clampage cave endovasculaire: expériences préliminaires chez le porc. Ann Chir. 2000;25:462-467.
33. Azoulay D, Bismuth H. Role of liver surgery and transplantation in patients with hepatic metastases from pancreatic endocrine tumors. In: Mignon M, Jensen RT, eds. Endocrine Tumors of the Pancreas. Basel, Switzerland: S Karger AG; 1995:461-476.
34. Libutti SK, Barlett DL, Fraker DL, Alexander HR. Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies. J Am Coll Surg. 2002;191:519-530.
35. de Wilt JH, Manusama ER, van Tiel ST, van Ijken MG, ten Hagen TL, Eggermont AMM. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer. 1999;80:161-166.
36. Shulman HM, Luk K, Deeg J, Shuman WB, Storb R. Induction of hepatic venoocclusive disease in dogs. Am J Pathol. 1987;126:114-125.
37. King PD, Perry MC. Hepatotoxicity of chemotherapeutic and oncologic agents. Gastroenterol Clin North Am. 1995;24:969-990.
38. van Ijken MGA, de Bruijn EA, de Boeck GD, ten Hagen TLM, van der Sijp JRM, Eggermont AMM. Isolated hypoxic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs. Ann Surg. 1998;228:763-770.
39. Thom AK, Alexander HR, Andrich MP, Barker WC, Rosenberg SA, Fraker DL. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan. J Clin Oncol. 1995;13:264-273.
40. Maekawa Y, Ku Y, Saitoh Y. Extracorporeal cisplatin removal using direct hemoperfusion under hepatic venous isolation for hepatic arterial chemotherapy: an experimental study on pharmacokinetics. Surg Today. 1993;23:58-62.
41. van der Wilt CL, Marinelli A, Pinedo HM, et al. The effect of different routes of administration of 5-fluorouracil on thymidylate synthase inhibition in the rat. Eur J Cancer. 1995;31A:754-760.
42. Bengala C, Pazzagli I, Innocenti F, et al. High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicinpaclitaxel-containing regimens in metastatic breast cancer (MBC). Ann Oncol. 2001;12:69-74.
43. Farabos C, Haaz MC, Gires P, Robert J. Hepatic extraction, metabolism, and biliary excretion of irinotecan in the isolated perfused rat liver. J Pharm Sci. 2001; 90:722-731.
44. de Roos WK, de Wilt JH, van Der Kaaden ME, et al. Isolated limb perfusion for local gene delivery: efficient and targeted adenovirus-mediated gene transfer into soft tissue sarcomas. Ann Surg. 2000;232:814-821.
45. Nakamoto T, Inagawa H, Takagi K, Soma G. A new method of antitumor therapy with a high dose of TNF perfusion for unresectable liver tumors. AnticancerRes. 2002;20:4087-4096.
46. Thorlacius H, Larmark M, Randell M, Hultberg B, Jeppsson B. Isolated liver perfusion permits administration of high doses of chemotherapeutic agents: comparison with hepatic artery infusion. Eur Surg Res. 2002;33:342-347.